Bromfenac/gatifloxacin/prednisolone ophthalmic Disease Interactions
There are 6 disease interactions with bromfenac / gatifloxacin / prednisolone ophthalmic.
NSAIDs (applies to bromfenac/gatifloxacin/prednisolone ophthalmic) GI toxicity
Major Potential Hazard, Moderate plausibility. Applicable conditions: Intestinal Anastomoses
Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can develop at any time, with or without warning symptoms. NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as: prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy. Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.
References
- (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
- (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
- (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
- (2002) "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories
- (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
- (2001) "Product Information. Clinoril (sulindac)." Merck & Co., Inc
- (2001) "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical
- (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
- (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
- (2001) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals
- (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
- (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
- (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Daypro (oxaprozin)." Searle
- (2001) "Product Information. Celebrex (celecoxib)." Searle
- (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
Ophthalmic corticosteroids (applies to bromfenac/gatifloxacin/prednisolone ophthalmic) ocular infections
Major Potential Hazard, High plausibility.
The use of ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; fungal diseases of ocular structures; mycobacterial infections, including tuberculosis, of the eye; and any acute, purulent, untreated ocular infections. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. In addition, administration of ophthalmic corticosteroids in severe ocular disease, especially acute herpes simplex keratitis, may lead to excessive corneal and scleral thinning, increasing the risk for perforation. In less serious ocular infections, therapy with ophthalmic corticosteroids may be administered but only with caution and accompanied by appropriate antimicrobial agents. Besides compromising host immune response, corticosteroids may also mask the symptoms of infection, thus hindering the recognition of potential ineffectiveness of the antibiotic therapy. If infection does not improve or becomes worse during administration of an ophthalmic corticosteroid, the drug should be discontinued and other appropriate therapy initiated.
References
- (2001) "Product Information. Vexol (rimexolone ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Lotemax (loteprednol ophthalmic)." Bausch and Lomb
- (2001) "Product Information. Pred Forte (prednisolone ophthalmic)." Allergan Inc
- (2001) "Product Information. Decadron Ocumeter (dexamethasone ophthalmic)." Merck & Co., Inc
- "Product Information. FML S.O.P. (fluorometholone ophthalmic)." Allergan Inc
- (2001) "Product Information. HMS (medrysone ophthalmic)." Allergan Inc
Ophthalmic corticosteroids (applies to bromfenac/gatifloxacin/prednisolone ophthalmic) ocular toxicities
Major Potential Hazard, High plausibility. Applicable conditions: Cataracts, Glaucoma/Intraocular Hypertension
Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure. If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children. The equatorial and posterior subcapsular portions of the lens should be examined for changes.
References
- Seale JP, Compton MR (1986) "Side-effects of corticosteroid agents." Med J Aust, 144, p. 139-42
- Godel V, Regenbogen L, Stein R (1978) "On the mechanism of corticosteroid-induced ocular hypertension." Ann Ophthalmol, 10, p. 191-6
- Francois J (1977) "Corticosteroid glaucoma." Ann Ophthalmol, 9, p. 1075-80
- Kitazawa Y (1976) "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol, 82, p. 492-5
- Butcher JM, Austin M, McGalliard J, Bourke RD (1994) "Bilateral cataracts and glaucoma induced by long term use of steroid eye drops." BMJ, 309, p. 43
- (2001) "Product Information. Vexol (rimexolone ophthalmic)." Alcon Laboratories Inc
- Leibowitz HM, Bartlett JD, Rich R, Mcquirter H, Stewart R, Assil K (1996) "Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids." Arch Ophthalmol, 114, p. 933-7
- Foster CS, Alter G, Debarge LR, Raizman MB, Crabb JL, Santos CI, Feiler LS, Friedlaender MH (1996) "Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis." Am J Ophthalmol, 122, p. 171-82
- (2001) "Product Information. Lotemax (loteprednol ophthalmic)." Bausch and Lomb
- (2001) "Product Information. Pred Forte (prednisolone ophthalmic)." Allergan Inc
- (2001) "Product Information. Decadron Ocumeter (dexamethasone ophthalmic)." Merck & Co., Inc
- "Product Information. FML S.O.P. (fluorometholone ophthalmic)." Allergan Inc
- (2001) "Product Information. HMS (medrysone ophthalmic)." Allergan Inc
NSAIDs (applies to bromfenac/gatifloxacin/prednisolone ophthalmic) heart failure
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure
Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations. These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.
References
- (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
- (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
- (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
- (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
- (2001) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals
- (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
- (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
- (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Daypro (oxaprozin)." Searle
- (2001) "Product Information. Celebrex (celecoxib)." Searle
- (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
- (2016) "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)
NSAIDs (applies to bromfenac/gatifloxacin/prednisolone ophthalmic) hyperkalemia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state. Caution is advised in patients with hyperkalemia.
References
- (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
- (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
- (2001) "Product Information. Celebrex (celecoxib)." Searle
NSAIDs (applies to bromfenac/gatifloxacin/prednisolone ophthalmic) hypertension
Moderate Potential Hazard, Moderate plausibility.
Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. NSAIDs should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.
References
- (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
- (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
- (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
- (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
- (2001) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals
- (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
- (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
- (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Daypro (oxaprozin)." Searle
- (2001) "Product Information. Celebrex (celecoxib)." Searle
- (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
- (2016) "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)
Bromfenac/gatifloxacin/prednisolone ophthalmic drug interactions
There are 383 drug interactions with bromfenac / gatifloxacin / prednisolone ophthalmic.
Bromfenac/gatifloxacin/prednisolone ophthalmic alcohol/food interactions
There are 2 alcohol/food interactions with bromfenac / gatifloxacin / prednisolone ophthalmic.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.